Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

The Impact of Continuous Lenalidomide Maintenance Treatment on People Living with Multiple Myeloma - a Single-Centre Qualitative Service Evaluation

Caroline Buck, Francisco Castillo, Elena Bettio, Kwee Yong, Annabel Mcmillan, Lydia Sarah Hui Lee, Xenofon Papanikolaou, Ke Xu, Charalampia Kyriakou, Neil Rabin, Ashutosh D. Wechalekar, Rakesh Popat, Joanne Land, Orla McCourt, Helen Poole, Rachel Tarling, Abigail Fisher, Jonathan Sive

Blood (2023) 142 (Supplement 1): 6640.

https://doi.org/10.1182/blood-2023-184914

Published: 2023

Journal Articles

Infection Risk and Use of Prophylaxis with Anti-BCMA Bispecific T Cell Engagers and Belantamab Mafodotin for Patients with Relapsed and Refractory Multiple Myeloma

Rakesh Popat, Kathleen Cheok, Amrutha Sridhar, Conor Feely, Catriona Mactier, Annabel Mcmillan, Ashutosh D. Wechalekar, Neil Rabin, Jonathan Sive, Charalampia Kyriakou, Ke Xu, Xenofon Papanikolaou, Shameem Mahmood, Kwee Yong, Lydia Sarah Hui Lee

Blood (2023) 142 (Supplement 1): 4702.

https://doi.org/10.1182/blood-2023-182725

Published: 2023

Journal Articles

Survey of the Relevance of Quality of Life (QoL) Questionnaires (QoLQs) Currently Used to Evaluate Multiple Myeloma (MM) Patients' Qol in Real-World MM Patients and Healthcare Professionals (HCPs)

Sotirios Bristogiannis, Yadanar Lwin, Catherine SY Lecat, Joanne Sowter, Orla McCourt, Emma Dowling, Nuno Correia, Neil K Rabin, Ke Xu, Jonathan Sive, Xenofon Papanikolaou, Rakesh Popat, Lydia Lee, Annabel McMillan, Sosana Delimpasi, Ashutosh D. Wechalekar, Kwee Yong, Charalampia Kyriakou

Blood (2022) 140 (Supplement 1): 12506–12507.

https://doi.org/10.1182/blood-2022-167272

Published: 2022

Journal Articles

Daratumumab, Bortezomib and Dexamethasone (DVd) at First Relapse for Patients with Relapsed/ Refractory Multiple Myeloma (RRMM): A UK Myeloma Research Alliance (UK-MRA) Real-World Multicentre Analysis

Blood (2021) 138 (Supplement 1): 4120.

https://doi.org/10.1182/blood-2021-147043

Published: 2021

Journal Articles

Serological Response to the BNT162b2 mRNA or Chadox-Ncov-19 COVID-19 Vaccine after First and Second Doses in Plasma Cell Disorder Patients: Influence of Host and Disease Factors

Blood (2021) 138 (Supplement 1): 1628.

https://doi.org/10.1182/blood-2021-149027

Published: 2021

Journal Articles

Subsequent Treatments, Responses and Survival in the Real World for Patients with Relapsed Multiple Myeloma Following Treatment with Lenalidomide

Jessica B Taube, MBBChir, Catherine SY Lecat, MBBS, Simon Cheesman, BPharm, Gabriel Wallis, Charalampia Kyriakou, Lydia Lee, Shameem Mahmood, Xenofon Papanikolaou, Christopher Parrish, MB BChir MA MRCP FRCPath PhD, Neil K Rabin, Sajitha Sachchithananthan, Jonathan Sive, MD, Ashutosh D. Wechalekar, Kwee Yong, Gordon Cook, Rakesh Popat

Blood (2019) 134 (Supplement_1): 4340.

https://doi.org/10.1182/blood-2019-128266

Published: 2019

Journal Articles

47 Genes Define Myeloma Cell Acquired Resistance to Bortezomib and Have Profound Prognostic Implications in Multiple Myeloma

Xenofon Papanikolaou, MD, Caleb K. Stein, MS, Ricky D Edmondson, PhD, Veronica Macleod, Ruslana Tytarenko, Bart Barlogie, MD PhD, Joshua Epstein, DSc, Christoph Heuck, MD

Blood (2015) 126 (23): 499.

https://doi.org/10.1182/blood.V126.23.499.499

Published: 2015

Journal Articles

A Prognostic 51-Gene Signature Linked to Abnormal Metaphase Cytogenetics Identifies Myeloma Patients Who Benefit from Fractionated Melphalan Dosing and Added Bortezomib, Thalidomide and Dexamethasone As Conditioning for Autologous Stem Cell Transplant

Blood (2015) 126 (23): 3181.

https://doi.org/10.1182/blood.V126.23.3181.3181

Published: 2015

Journal Articles

The Composition and Clinical Impact of Focal Lesions and Their Impact on the Microenvironment in Myeloma

Shmuel Yaccoby, PhD, Joshua Epstein, DSc, Sarah K. Johnson, PhD, Pingping Qu, PhD, Frits van Rhee, MD PhD, Yogesh Jethava, MB, MRCP, MD FRCPath, Caleb K. Stein, MS, Emily Hansen, Alan Mitchell, Maurizio Zangari, MD, Christoph Heuck, MD, Rashid Z Khan, MD, Xenofon Papanikolaou, MD, Faith E Davies, MD, Antje Hoering, PhD, John Crowley, PhD, Niels Weinhold, PhD, Bart Barlogie, MD PhD, Gareth J Morgan, MDPhD

Blood (2015) 126 (23): 1806.

https://doi.org/10.1182/blood.V126.23.1806.1806

Published: 2015

Journal Articles

Spectrum of Cerebrovascular Disease in Multiple Myeloma Patients Undergoing Chemotherapy

Archana Hinduja, MD, Kaustubh Limaye, MD, Rahul Ravilla, MD, Appalanaidu Sasapu, MD MS, Xenofon Papanikolaou, MD, Sarah Waheed, MD

Blood (2015) 126 (23): 5498.

https://doi.org/10.1182/blood.V126.23.5498.5498

Published: 2015

Journal Articles

Extending Metronomic Therapy to 28 Days (metro28) for Relapsed Refractory Multiple Myeloma (RRMM)

Xenofon Papanikolaou, MD, Carolina Schinke, MD, Sharmilan Thanendrarajan, MD, Adam Rosenthal, Nathan Petty, MS, Maurizio Zangari, MD, Christoph Heuck, MD, Frits van Rhee, MD PhD, Joshua Epstein, DSc, Shmuel Yaccoby, PhD, Gareth J Morgan, MDPhD, Faith E Davies, MD, Bart Barlogie, MD PhD

Blood (2015) 126 (23): 5395.

https://doi.org/10.1182/blood.V126.23.5395.5395

Published: 2015

Journal Articles

PET-CT Defined Focal Lesions at Baseline and Day 7 Predict Outcome in GEP 70 Defined High Risk Multiple Myeloma Patients

Yogesh Jethava, MB, MRCP, MD FRCPath, Rachel Hunter-Merrill, Gareth J Morgan, MD PhD, Rashid Z Khan, MD, Aasiya Matin, MD, Christoph Heuck, MD, Maurizio Zangari, MD, Xenofon Papanikolaou, MD, Frits van Rhee, MD PhD, Faith E Davies, MD, Bart Barlogie, MD PhD

Blood (2014) 124 (21): 3407.

https://doi.org/10.1182/blood.V124.21.3407.3407

Published: 2014

Journal Articles

Higher Expressions of PTH Receptor Type 1 and/or 2 in Bone Marrow Is Associated to Longer Survival in Newly Diagnosed Myeloma Patients Enrolled in Total Therapy 3

Maurizio Zangari, MD, Caleb K Stein, MS, Shmuel Yaccoby, PhD, Donghoon Yoon, PhD, Christoph Heuck, MD, Yogesh Jethava, MB, MRCP, MD FRCPath, Donald Johann, MD MS, Rashid Z Khan, MD, Xenofon Papanikolaou, MD, Frits van Rhee, MD PhD, Faith E Davies, MD, Gareth J Morgan, MD PhD, Bart Barlogie, MD PhD

Blood (2014) 124 (21): 3409.

https://doi.org/10.1182/blood.V124.21.3409.3409

Published: 2014

Journal Articles

Waldenstrom's Macroglobulinemia Associated Bone Disease the UAMS Experience

Xenofon Papanikolaou, MD, Sarah Waheed, MD, Bart Barlogie, MD PhD, Daisy V. Alapat, MD, Donghoon Yoon, PhD, Manoj Kumar, MD, Aasiya Matin, MD, Hongyun Zhu, MD, Cerisse Harcourt, APN, Maurizio Zangari, MD

Blood (2014) 124 (21): 2999.

https://doi.org/10.1182/blood.V124.21.2999.2999

Published: 2014

Journal Articles

Low-Dose 28-Day Metronomically Scheduled Therapy (METRO) for Newly Diagnosed High-Risk Multiple Myeloma: A Pilot Study

Rashid Z Khan, MD, Yogesh Jethava, MB, MRCP, MD FRCPath, Xenofon Papanikolaou, MD, Caleb K Stein, MS, Adam Rosenthal, Christoph Heuck, MD, Frits van Rhee, MD PhD, Jameel Muzaffar, MD, Maurizio Zangari, MD, Clyde Bailey, Phillip Farmer, Bart Barlogie, MD PhD

Blood (2014) 124 (21): 5770.

https://doi.org/10.1182/blood.V124.21.5770.5770

Published: 2014

Journal Articles

Further Evolution of Metronomic Therapy Extended to 28 Days (Metro28) for Relapsed Refractory Multiple Myeloma (RRMM)

Xenofon Papanikolaou, MD, Rashid Z Khan, MD, Adam Rosenthal, Clyde Bailey, Yogesh Jethava, MB, MRCP, MD FRCPath, Christoph Heuck, MD, Susan B. Panozzo, BS, Maurizio Zangari, MD, Frits van Rhee, MD PhD, Carolina Schinke, MD, Faith E Davies, MD, Gareth J Morgan, MD PhD, Bart Barlogie, MD PhD

Blood (2014) 124 (21): 2128.

https://doi.org/10.1182/blood.V124.21.2128.2128

Published: 2014

Journal Articles

Identifying a Gene Expression (GEP)-Based Model Predicting for Progression from AMM to Cmm Requiring Therapy in S0120 Patients Treated at Mirt

Rashid Z Khan, MD, Christoph Heuck, MD, Adam Rosenthal, Caleb K Stein, MS, Joshua Epstein, DSc, Shmuel Yaccoby, PhD, Xenofon Papanikolaou, MD, Yogesh Jethava, MB, MRCP, MD FRCPath, Maurizio Zangari, MD, Frits Van Rhee, Madhav V. Dhodapkar, MD, Gareth J Morgan, MD PhD, Antje Hoering, PhD, John Crowley, PhD, Bart Barlogie, MD PhD

Blood (2014) 124 (21): 2078.

https://doi.org/10.1182/blood.V124.21.2078.2078

Published: 2014

Journal Articles

Flow Cytometry Defined Cytoplasmic Immunoglobulin Index Is a Major Prognostic Factor for Progression of Asymptomatic Monoclonal Gammopathies to Clinical Multiple Myeloma

Xenofon Papanikolaou, MD, Adam Rosenthal, Rashid Z Khan, MD, Joshua Epstein, DSc, Christoph Heuck, MD, Madhav V. Dhodapkar, MD, Yogesh Jethava, MB, MRCP, MD FRCPath, Maurizio Zangari, MD, Omar Atiq, MD, Sarah Waheed, MD, Faith Davies, MD, Gareth J Morgan, MD PhD, Bart Barlogie, MD PhD

Blood (2014) 124 (21): 2079.

https://doi.org/10.1182/blood.V124.21.2079.2079

Published: 2014

Journal Articles

Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120)

Madhav V. Dhodapkar, Rachael Sexton, Sarah Waheed, Saad Usmani, Xenofon Papanikolaou, Bijay Nair, Nathan Petty, John D. Shaughnessy, Jr, Antje Hoering, John Crowley, Robert Z. Orlowski, Bart Barlogie

Blood (2014) 123 (1): 78–85.

https://doi.org/10.1182/blood-2013-07-515239

Published: 2014

Includes: Supplemental data

Journal Articles

Characteristics and Prognosis Of IgM Multiple Myeloma

Shebli Atrash, MD, Qing Zhang, PhD, Xenofon Papanikolaou, MD, Christoph Heuck, MD, Aziz Bakhous, M.D., Jameel Muzaffar, MD, Al-Ola Abdallah, MD, Bart Barlogie, MD, PhD

Blood (2013) 122 (21): 1881.

https://doi.org/10.1182/blood.V122.21.1881.1881

Published: 2013

NARROW

The Impact of Continuous Lenalidomide Maintenance Treatment on People Living with Multiple Myeloma - a Single-Centre Qualitative Service Evaluation

Infection Risk and Use of Prophylaxis with Anti-BCMA Bispecific T Cell Engagers and Belantamab Mafodotin for Patients with Relapsed and Refractory Multiple Myeloma

Survey of the Relevance of Quality of Life (QoL) Questionnaires (QoLQs) Currently Used to Evaluate Multiple Myeloma (MM) Patients' Qol in Real-World MM Patients and Healthcare Professionals (HCPs)

Daratumumab, Bortezomib and Dexamethasone (DVd) at First Relapse for Patients with Relapsed/ Refractory Multiple Myeloma (RRMM): A UK Myeloma Research Alliance (UK-MRA) Real-World Multicentre Analysis

Serological Response to the BNT162b2 mRNA or Chadox-Ncov-19 COVID-19 Vaccine after First and Second Doses in Plasma Cell Disorder Patients: Influence of Host and Disease Factors

Subsequent Treatments, Responses and Survival in the Real World for Patients with Relapsed Multiple Myeloma Following Treatment with Lenalidomide

47 Genes Define Myeloma Cell Acquired Resistance to Bortezomib and Have Profound Prognostic Implications in Multiple Myeloma

A Prognostic 51-Gene Signature Linked to Abnormal Metaphase Cytogenetics Identifies Myeloma Patients Who Benefit from Fractionated Melphalan Dosing and Added Bortezomib, Thalidomide and Dexamethasone As Conditioning for Autologous Stem Cell Transplant

The Composition and Clinical Impact of Focal Lesions and Their Impact on the Microenvironment in Myeloma

Spectrum of Cerebrovascular Disease in Multiple Myeloma Patients Undergoing Chemotherapy

Extending Metronomic Therapy to 28 Days (metro28) for Relapsed Refractory Multiple Myeloma (RRMM)

PET-CT Defined Focal Lesions at Baseline and Day 7 Predict Outcome in GEP 70 Defined High Risk Multiple Myeloma Patients

Higher Expressions of PTH Receptor Type 1 and/or 2 in Bone Marrow Is Associated to Longer Survival in Newly Diagnosed Myeloma Patients Enrolled in Total Therapy 3

Waldenstrom's Macroglobulinemia Associated Bone Disease the UAMS Experience

Low-Dose 28-Day Metronomically Scheduled Therapy (METRO) for Newly Diagnosed High-Risk Multiple Myeloma: A Pilot Study

Further Evolution of Metronomic Therapy Extended to 28 Days (Metro28) for Relapsed Refractory Multiple Myeloma (RRMM)

Identifying a Gene Expression (GEP)-Based Model Predicting for Progression from AMM to Cmm Requiring Therapy in S0120 Patients Treated at Mirt

Flow Cytometry Defined Cytoplasmic Immunoglobulin Index Is a Major Prognostic Factor for Progression of Asymptomatic Monoclonal Gammopathies to Clinical Multiple Myeloma

Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120)

Characteristics and Prognosis Of IgM Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only